By Gerelyn Terzo, Global AgInvesting Media
Crop disease prevention and biological resilience technologies continue to attract investor attention, with Resurrect Bio emerging as the latest company to secure fresh backing. In a milestone cheered by the industry, the London-based agricultural biotechnology company, which helps crops to defeat disease, has clinched an impressive $8.1 million initial close of its Series A financing round.
Led by led by Corteva Agriscience, the round extended to other participants including Calculus Capital, Pymwymic, U.K. Innovation & Science Seed Fund, SynBioVen and AgFunder. Proceeds will be directed toward ramping up the production of its native crop protection traits and to bolster the profile of its computational protein-protein interaction screening tool, FloraFold AI.
The funding round highlights sustained investor appetite for sustainable crop protection technologies. Resurrect Bio has built a proprietary platform that harnesses AI to identify plant disease-resistance genes that pathogens have effectively silenced. This resurrection concept sits at the core of the company’s model: by combining its FloraFold computational biology engine with high-throughput plant screening, Resurrect Bio isolates compromised genetic defenses and applies precise gene editing to make subtle corrections, allowing crops to recover their natural ability to combat threats. The approach is designed to equip farmers with an innovative, science-driven way to protect yields as plant diseases continue to pose risks to global food security.
In a LinkedIn post, Resurrect Bio shared its ambitious growth plans, stating, “We are on a mission to become the world’s leading plant disease resistance company and this investment brings us one step closer.”
Harnessing its proprietary technology Resurrects R-genes, Resurrect Bio gives crops the tools to defend themselves against disease. The funding highlights continued capital interest in next-generation crop protection strategies, particularly those centered on genetic and biological defenses. As agricultural producers contend with rising disease pressures, regulatory shifts and cost sensitivities, technologies aimed at strengthening plant resilience are increasingly drawing strategic and financial investors alike.
Resurrect Bio CEO Dr. Cian Duggan stated, “We’re thrilled to have secured this investment from such a distinguished group of partners who share our vision of delivering durable disease resistance to farmers. With Corteva’s leadership and the support of Calculus Capital, Pymwymic and our existing investors, we’re now positioned to scale our platform and deliver multiple resistance traits to the seed industry.”
Corteva Catalyst Sr. Director Mathias Müller commented, “We’re excited to share the news of our investment in Resurrect Bio. Resurrect’s platform for the restoration of plant immunity in instances where pathogens have defeated natural disease resistance mechanisms, is a unique, novel approach to sustainably develop crops that will naturally exhibit the resilience our farmers need in the face of changing climate and pathogen profiles”
Founded in 2021, Resurrect Bio is a spinoff from The Sainsbury Laboratory, whose executive director Nick Talbot said, “Resurrect Bio is a TSL spinout company founded on ground-breaking science, that will use precision breeding technology to combat some of the most important diseases facing global agriculture. We are very proud of the team led by Cian Duggan and excited to see their next stage of development.”
The content put forth by Global AgInvesting News and its parent company Arc Network LLC is intended to be used and must be used for informational purposes only. All information or other material herein is not to be construed as legal, tax, investment, financial, or other advice. Global AgInvesting and Arc Network LLC are not a fiduciary in any manner, and the reader assumes the sole responsibility of evaluating the merits and risks associated with the use of any information or other content on this site.